Helsinn Group (Helsinn), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and BridgeBio Pharma (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic